Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Amgen Inc.
Formerly called
Applied Molecular Genetics
(1980–1983)
Type
Public
Traded as NASDAQ: AMGN
NASDAQ-100 Component
S&P 100 Component
S&P 500 Component
SEHK: 4332
Industry Biotechnology
Founded 1980
Headquarters Thousand Oaks, California, U.S.
Key people
Robert A. Bradway
(Chairman, President, and CEO)
Products Epogen, Aranesp, Kineret, Enbrel, Neulasta, Neupogen, Nplate, Vectibix, Prolia, Xgeva, and Sensipar/Mimpara.
Revenue Increase US$22.99 billion (2016)
Operating income
Increase US$9.79 billion (2016)
Net income
Increase US$7.72 billion (2016)
Total assets Increase US$77.63 billion (2016)
Total equity Increase US$29.88 billion (2016)
Number of employees
19,200 (December 2016)
Website www.amgen.com

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988, followed by Kevin W. Sharer in 2000. Robert A. Bradway became Amgen’s president and chief executive officer in May 2012 following Sharer's retirement.

The company has made at least five major corporate acquisitions.

The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:

Amgen
(Founded 1983 as Applied Molecular Genetics)

Synergen Inc
(Acq 1994)

Kinetix Pharmaceuticals Inc
(Acq 2000)

Immunex Corporation
(Acq 2002)

Tularik Inc (Acq 2004)

Abgenix Inc
(Acq 2006)

Avidia Inc
(Acq 2006)

Alantos Pharmaceuticals
(Acq 2007)

Ilypsa Inc
(Acq 2007)

Alantos Pharmaceuticals Holdings Inc
(Acq 2007)

BioVex Group Inc
(Acq 2011)

Laboratório Químico Farmacêutico Bergamo Ltda
(Acq 2011)

Micromet Inc
(Acq 2012)

Mustafa Nevzat İlaç
(Acq 2012)

KAI Pharmaceuticals
(Acq 2012)

deCODE genetics
(Acq 2012)

Onyx Pharmaceuticals
(Acq 2013)

NextCODE genetics
(Spun off 2013)

Dezima Pharma
(Acq 2015)

Catherex
(Acq 2015)

As of December, 2013, Amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions (conditions lists are highly generalized; see each article for more detail):

As of December 2013, Amgen had 11 drugs in Phase III clinical trials.

In November 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without. Later in the same week, the company (in conjunction with AstraZeneca) reported positive results for brodalumab in a phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.

In March 2015, the company announced it would license its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.

In June 2015 Amgen presented Phase 2 clinical trial data for their anti-CGRP antibody AMG 334 for migraine.

Investment goal date:
Dividends reinvested
Amgen Inc. AMGN report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-04-25
--
--
Q4 2017
2018-01-31
--
--
Q3 2017
2017-10-25
3.2700
2.7600
Q2 2017
2017-07-25
3.2700
2.9100
Q1 2017
2017-04-26
3.1500
2.7900
Q4 2016
2017-02-02
2.8900
2.5900
Q3 2016
2016-10-27
3.0200
2.6800
Q2 2016
2016-07-27
2.8400
2.4700
Q1 2016
2016-04-28
2.9000
2.5000
Q4 2015
2016-01-28
2.6100
2.3700
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Bank of New York Mellon Corp
8555356
BlackRock Fund Advisors
14594759
BlackRock Inc.
48541514
BlackRock Institutional Trust Company, N.A.
21078389
Capital Research Global Investors
57325135
Clearbridge Investments, LLC
8761411
FMR LLC
54412531
GEODE CAPITAL MANAGEMENT, LLC
7469454
Invesco Ltd.
9944576
MORGAN STANLEY
8714449
NORTHERN TRUST CORP
9443322
PRIMECAP MANAGEMENT CO/CA/
24105794
STATE STREET CORP
33673148
Vanguard Group, Inc
51657215
WELLINGTON MANAGEMENT CO LLP
7425112
Major Shareholders
Name Relationship
Total Shares
Holding stocks
AMGEN INC
0.0700% (541399)
AMGN / TLOG /
SCOTT DAVID J
0.0100% (93949)
AMGN /
MCNAMEE BRIAN M
0.0100% (102516)
AMGN /
OMENN GILBERT S
0.0200% (180547)
AMGN / ESPR / GALT /
COFFMAN VANCE D
0.0100% (43041)
AMGN / DE / MMM /
HOOPER ANTHONY C
0.0300% (203402)
AMGN /
Michael A Kelly
0.0100% (39177)
AMGN /
Graham Jonathan P
0.0100% (44165)
AMGN / DHR /
Bradway Robert A
0.0500% (396242)
AMGN / BA / NSC /
Meline David W
0.0100% (47920)
AMGN / MMM / TRW /
Peacock Jonathan M
0.0100% (94414)
AMGN / KITE /
Harper Sean E
0.0100% (57631)
AMGN /
Harper Sean E
0.0100% (59156)
AMGN /
% ()